ABBV vs INTU: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Intuit Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-29.
AbbVie Inc. · Healthcare
$197.69
+6.3% upside to fair value
Grade C
High Quality
VS
Intuit Inc. · Technology
$396.57
+45.0% upside to fair value
High Conviction
Grade A-
QuantHub Verdict
INTU has more upside to fair value
(+45.0%).
INTU trades at a lower forward P/E
(19.5x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
INTU |
| Current Price |
$197.69 |
$396.57 |
| Fair Value Estimate |
$210.22 |
$575.03 |
| Upside to Fair Value |
+6.3%
|
+45.0%
|
| Market Cap |
$349.7B |
$110.4B |
| Forward P/E |
83.3x
|
19.5x
|
| EV / EBITDA |
23.4x
|
19.0x
|
| Price / Sales |
5.7x
|
5.9x
|
| Price / FCF |
18.7x
|
18.1x
|
| Revenue Growth YoY |
+10.0%
|
+15.6%
|
| Gross Margin |
70.2%
|
80.8%
|
| Operating Margin |
26.7%
|
26.1%
|
| Return on Equity |
-361.6%
|
19.6%
|
| Dividend Yield |
0% |
1.17% |
| FCF Yield |
5.35%
|
5.51%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology, neuroscience, oncology, and aesthetics. The company benefits from a durable competitive moat driven by blockbuster drugs such as Skyrizi and Rinvoq, which are experiencing rapid growth and offsetting declines from Humira due to biosimilar competition. Despite a high trailing and forwa…
Intuit is a near-monopoly financial operating system for 60+ million American households and small businesses. TurboTax handles 40%+ of US e-filed returns; QuickBooks is so deeply embedded in SMB workflows it has become the default accounting standard. The stock has fallen 51% from its 2025 high as markets price in AI disruption that has not materialized at scale and may not, since tax complexity…
Accumulation Zones
| Metric |
ABBV |
INTU |
| Zone Low |
$157.66 |
$431.27 |
| Zone High |
$178.69 |
$488.78 |
| In Buy Zone? |
No
|
Yes
|